Clinical trials: Hemophilia a
Hemophilia
Myofascial Therapy in Patients With Hemophilic Arthropathy
Designing a treatment protocol using myofascial therapy for the treatment of pain and restrictions on mobility in patients with hemophilic arthropathy of the knee and ankle.
- Trial name
- He-Fascial (NCT02433782)
- Testing
- Myofascial therapy
- Where
- Spain
- Volunteers
- 25 people
- Sponsor
- Universidad Católica San Antonio de Murcia
Hemophilia A With Inhibitors
A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)
The primary purpose of this study was to describe the time to tolerization (i.e., ITI success) with rFVIIIFc in participants within a maximum of 48 weeks (12 months) of ITI treatment.
- Trial name
- NCT03093480
- Testing
- rFVIIIFc
- Where
- 37 sites in United States, Belgium and 8 more
- Volunteers
- 16 people
- Sponsor
- Bioverativ, a Sanofi company
Hemophilia
Genetic Susceptibility to Factor VIII Inhibitors
This international study will identify genetic factors that may influence the development of inhibitory antibodies in patients with hemophilia A after treatment with factor VIII.
- Trial name
- NCT00344435
- Where
- Sweden
- Volunteers
- 1,187 people
- Sponsor
- National Cancer Institute (NCI)
Health Services Accessibility, Blood Coagulation Factor Deficiencies
Accessibility of Prophylaxis and On-demand Treatment for Persons With Haemophilia and Other Coagulation Deficiencies
The current treatment of people with haemophilia and other bleeding deficiencies is largely based on clotting factor replacement therapy. The injections can be repeated several times a week according to a personalized schedule.
- Trial name
- PHAREO (NCT04775888)
- Where
- 34 sites in France
- Volunteers
- 500 people
- Sponsor
- RESCUe - RESeau Cardiologie Urgence / RESUVal - RESeau des Urgences de la vallée du Rhône
Hemophilia
Isokinetic Strength Training On Functional Performance
Hemophilia is a congenital , recessive clotting disease featured by cerebra ( The most dangerous ) and musculoskeletal (the most common and disabling) hemorrhages .
- Trial name
- Isokinetic (NCT07035080)
- Testing
- interferential therapy, tradional physical therapy
- Volunteers
- 30 people
- Sponsor
- Kafrelsheikh University
Haemophilia A
Study of the Efficacy of Human Recombinant Factor VIII (Kogenate FS) Reconstituted in Pegylated Liposomes.
Primary efficacy endpoint: To study whether there is a difference in the length of the bleeding free periods between infusion of FVIII that is reconstituted with 22.1, 12.6, or 4.2 mg of pegylated liposomes per kg bwt compared…
- Trial name
- NCT00245297
- Testing
- Kogenate FS, reconstituted in a suspension of liposomes
- Where
- 3 sites in Russia
- Volunteers
- 16 people
- Sponsor
- Recoly N.V.
Hemophilia A
Safety,Efficacy and Pharmacokinetics Evaluation of SCT800 in Previously Treated Paediatric Patients With Severe Haemophilia A.
This study is a multicenter phase III uncontrolled open-label trial to evaluate the efficacy,safety and pharmacokinetics of SCT800 in regular prophylaxis and perioperative treatment in patients (<12 years old) with severe…
- Trial name
- NCT03947320
- Testing
- Recombinant Human Coagulation FVIII
- Volunteers
- 70 people
- Sponsor
- Sinocelltech Ltd.
Hemophilia, Hemophilia B
Study Evaluating Liver Transplantation in Haemophilia Patients in Spain
This study will analyze survival and outcome of patients with severe haemophilia who undergo liver transplantation in Spain
- Trial name
- NCT00927992
- Testing
- Epidemiological Non interventional
- Volunteers
- 11 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Hemophilia A
Joint Health, Balance and Quality of Life in Adults With Hemophilia A
Hemophilia is a hereditary bleeding disorder characterized by recurrent bleeding episodes, particularly into joints and muscles, leading to chronic musculoskeletal complications.
- Trial name
- NCT07523399
- Where
- Turkey (Türkiye)
- Volunteers
- 36 people
- Sponsor
- Yuzuncu Yil University
Hemophilia A, Congenital
Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis
The primary objective of this study is to investigate weekly prophylaxis dosing regimens used in standard clinical practice. In addition the study will capture reported bleed rate, pattern of change in KOVALTRY prophylaxis dose…
- Trial name
- TAURUS (NCT02830477)
- Testing
- Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973
- Where
- 25 sites in United States, Belgium and 11 more
- Volunteers
- 313 people
- Sponsor
- Bayer
Hemophilia A
An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.
The primary objectives of the study are to evaluate the efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (FRSW107) in the Prevention and Treatment of Bleeding in patients with hemophilia A.
- Trial name
- NCT04456387
- Testing
- Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection
- Where
- 17 sites in China
- Volunteers
- 119 people
- Sponsor
- Zhengzhou Gensciences Inc
Healthy Participants
A Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, PK/PD Characteristics, and Efficacy of SCTB10
Phase Ia to evaluate the safety, tolerability, immunogenicity, and pharmacokinetics of SCTB10 following a single dose in healthy participants
- Trial name
- NCT07847697
- Testing
- SCTB10
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Haemophilia B
A Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B in France
Alprolix (rFIXFc) is a recombinant extended half-life coagulation factor product. The purpose of this non-interventional study is to describe the real-world usage and effectiveness of Alprolix in the on-demand and prophylactic…
- Trial name
- B-SURE (NCT03655340)
- Testing
- Alprolix
- Where
- 18 sites in France
- Volunteers
- 91 people
- Sponsor
- Swedish Orphan Biovitrum
Hemophilia A
Recombinant Factor VIIa (NovoSeven) on Restoring Coagulation Activation
The purpose of the study is to compare the effects of recombinant factor VIIa (NovoSeven) on restoring coagulation activation between patients with hemophilia A and antibodies to factor VIII and normal subjects (controls) by use…
- Trial name
- NCT00375323
- Testing
- NovoSeven
- Where
- Austria
- Sponsor
- Medical University of Vienna
Hemophilia
The Dynamic Interplay Between Bleeding Phenotype and Baseline Factor Level in Moderate and Mild Hemophilia A and B
There are large inter-individual differences in the bleeding pattern of patients with moderate or mild hemophilia. The major determinant of bleeding phenotype is the level of coagulant factor VIII or IX.
- Trial name
- DYNAMO (NCT03623295)
- Testing
- Blood sample, Questionnaire, MRI-imaging
- Where
- 17 sites in Australia, Austria and 8 more
- Volunteers
- 304 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Hemophilia B
IMMUNINE Pre-Treatment Study
The primary objective of this study is to prospectively document the exposure to IMMUNINE and to monitor FIX inhibitors over a period of approximately 20 to 50 exposure days while receiving prophylactic treatment in up to 50…
- Trial name
- NCT01128881
- Testing
- Factor IX Concentrate (purified, virus-inactivated)
- Where
- 18 sites in Argentina, Brazil and 8 more
- Volunteers
- 57 people
- Sponsor
- Baxalta now part of Shire
Hemophilia
Allogenic Bone Marrow Derived Mesenchymal Stem Cell Therapy in Cases of Hemophilia
Hemophilia is caused by a single-gene defect resulting in familial bleeding disorder. Small increase in gene products could transform a severe form of hemophilia into a mild one.
- Trial name
- NCT02108132
- Testing
- Cellular therapy
- Where
- Egypt
- Volunteers
- 20 people
- Sponsor
- Cairo University
Congenital Bleeding Disorder, Haemophilia B
Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B
This trial is conducted in Europe, Japan and the United States of America (USA). The aim of this clinical trial is to investigate the safety and pharmacokinetics (the determination of the concentration of the administered…
- Trial name
- NCT00956345
- Testing
- nonacog beta pegol
- Where
- 19 sites in United States, Denmark and 6 more
- Volunteers
- 18 people
- Sponsor
- Novo Nordisk A/S
Hemophilia A, Hemophilia B
The Effect of Patient Counseling on Adolescent Hemophilia Patient Compliance With Bleeding Logs
The study will see if counselling adolescents with severe or moderate Hemophilia A or B results in increased compliance in the maintenance of bleeding logs.
- Trial name
- NCT00212459
- Testing
- Counseling, Control
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- New York Presbyterian Hospital
Hemophilia A, Congenital Factor VIII (FVIII) Deficiency
ADVATE 2 mL Post-Authorization Safety Surveillance (PASS)
This is a Post-Authorization Safety Surveillance (PASS) study designed to collect data on the safety and effectiveness of ADVATE reconstituted in 2 mL Sterile water for injection (SWFI) during routine clinical practice in…
- Trial name
- NCT02093741
- Testing
- Octocog alfa (recombinant human coagulation factor VIII) [ADVATE]
- Where
- 17 sites in France, Germany and 2 more
- Volunteers
- 65 people
- Sponsor
- Baxalta now part of Shire